Oric Plans 360-Patient Phase 3 Of Lung Cancer Drug Enozertinib In First Half Of 2027
The drugmaker presented Phase 1b data at ESMO and said FDA talks cleared the design of its Redwood-1 trial.
Oric Pharmaceuticals, a clinical-stage company developing cancer drugs meant to overcome treatment resistance, plans to start a global Phase 3 trial of its lung cancer drug enozertinib in the first half of 2027. The company said Friday the plan rests on End-of-Phase 1 talks with the FDA and on Phase 1b data shown at the ESMO Congress.
Redwood-1 design
The trial, called Redwood-1, plans to enroll about 360 patients with PACC and L861X mutations of the EGFR gene, including people with untreated brain metastases. Half are to get 80 mg of enozertinib once daily, and half their doctor's choice of osimertinib or afatinib, according to the 8-K.
There are two main goals: response rate by blinded independent central review, for potential accelerated approval, and progression-free survival by that review, for full approval. Overall survival and intracranial response rate are key secondary endpoints. Oric's slides say the FDA aligned with it on the patient population, control arm, endpoints and statistical method.
Phase 1b numbers
The data cover 26 patients treated at 80 mg daily as of a September 4, 2026 cutoff. Among 25 response-evaluable patients, 84% (21 of 25) had a confirmed systemic response by investigator, and 80% by independent review. Among 10 patients with measurable brain lesions, the confirmed intracranial response rate by investigator was 70%.
The Kaplan-Meier six-month landmark progression-free survival was 88%. Median progression-free survival and duration of response are immature, and most patients remain on treatment.
Brain metastases were present in 65% of patients at baseline, which the company says is more than double the rate in competitor datasets. Six patients (23%) had Grade 3 treatment-related adverse events, all resolved with dose changes, and none stopped treatment because of them. In a blood-test analysis of 22 patients, 82% reached full clearance of EGFR-mutant tumor DNA, which the company says has been linked to better survival in prior Phase 3 lung cancer trials.
A pipeline built on two drugs
Oric has no approved products. Enozertinib is one of its two lead candidates, alongside the prostate cancer drug rinzimetostat, and both are in Phase 1b trials. At Thursday's close ORIC shares were $13.63, down about 1.6% for that session, before the news came out Friday.
The company's timeline slide shows Phase 1b data for the exon 20 mutation population in mid-2027. That data is meant to inform a possible second Phase 3 trial.
Redwood-1 is slated to start in the first half of 2027, with exon 20 data due around mid-year.
Sources
- 8-K Filing — Oric Pharmaceuticals, Inc. (ORIC) — SEC EDGAR
- Exhibit d152009dex991.htm — Oric Pharmaceuticals, Inc. 8-K exhibit — SEC EDGAR
- ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 — Yahoo Finance
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Data — globenewswire.com